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Background: Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic
administration of low-dose chemotherapy at regular short intervals. We investigated the optimal metronomic dose
of oral vinorelbine when given as monotherapy in patients with metastatic cancer.
Methods: Patients with recurrent metastatic breast (BC), prostate (PC) or non-small cell lung cancer (NSCLC) and
adequate organ functions were randomly assigned to 30, 40 or 50 mg vinorelbine, taken orally three times a week.
Treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or maximum
24 months. Primary endpoint was time-to-treatment failure (TTF) and secondary were progression-free survival (PFS),
toxicity, changes in blood concentrations of angiogenesis-associated biomarkers and pharmacokinetics.
Results: Seventy-three patients were enrolled. Four-month TTF rate did not differ between the three arms: 25.9%
(11.1%-46.2% 95% Confidence Interval), 33.3% (15.6%-55.3%) and 18.2% (5.2%-40.3%) for the 30 mg, 40 mg and
50 mg arms (p-value = 0.56). Objective response was seen in 2 patients with NSCLC (treated at 30 and 50 mg
respectively), one with BC (at 40 m g) and one with PC (at 50 mg) and lasted from 4 to 100 weeks, with maximum
response duration achieved at 50 mg. Adverse events were mild and negligible and did not differ between the
three arms. Blood levels of vinorelbine reached steady state from the second week of treatment and mean values
for the 30, 40 and 50 mg were respectively 1.8 ng/ml (SD 1.10), 2.2 ng/ml (SD 1.87) and 2.6 ng/ml (SD 0.69). Low
pre-treatment blood concentrations of FGF2 and IL8 predicted favorable response to therapy (p values 0.02 and
0.006, respectively), while high levels of TEK gene transcript predicted treatment resistance.
Conclusions: Considering the antitumor activity and response duration, the negligible toxicity of the highest dose
investigated and the lack of drug accumulation over time, we suggest that 50 mg given three times a week is the
optimal dose for metronomic oral vinorelbine. Further investigation of metronomic oral vinorelbine (MOVIN) at this
dose is warranted in combination with conventional chemotherapy regimens and targeted therapies.
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Systemic therapy of metastatic cancers has moderately
progressed over the last decade. Conventional chemo-
therapy appears to have reached a plateau in efficacy for
most major solid cancers [1,2] and a number of promis-
ing targeted therapeutics have failed to meet their objec-
tives [3,4].
Metronomic chemotherapy (MC) has developed as a
patient-friendly therapy on the concept to induce prolonged
cancer control without significant side effects even in frail
patients [5-9]. It involves chronic administration of low-
dose chemotherapy at regular short intervals and mechan-
istically it stands between targeted anti-angiogenic therapy
and conventional chemotherapy, complementing known
shortcomings of both [10,11]. Most approved antiangiogenic
drugs are inhibitors of the VEGF/VEGFR pathway of
endothelial cells and demonstrate short-living clinical ac-
tivity possibly because of rebound emergence of alterna-
tive angiogenic “escape” pathways [12-16]. Conventional
application of cytotoxic drugs at maximum tolerated doses
(MTD) aims to induce highest possible apoptosis on can-
cer cells, but it also affects healthy proliferating tissues
and requests treatment-free intervals to allow recovery
from toxicities. However these treatment gaps may fa-
cilitate repair of damaged tumor vasculature rendering
cancers aggressive and resistant [17,18]. MC seems to
have the capability to bridge weaknesses of both targeted
antiangiogenic therapy and conventional chemotherapy
because it induces a pathway-independent inhibition of
function and proliferation of tumor endothelial cells
and in addition it can damage cancer cells, restore im-
mune response and induce tumor dormancy [11,19-21].
In a previously published phase 1A study we defined
pharmacokinetics and a dose range of metronomic oral
vinorelbine that can safely be given to patients with
advanced cancer and provided clinical evidence of the
antiangiogenic basis of this therapy [22]. We now report
the results of a dose selection randomized trial registered
at www.clinicaltrials.gov (Trial ID NCT00278070) that
aimed to define the optimal metronomic dose of oral
vinorelbine by considering clinical end points, pharma-
cokinetic data and correlative biomarkers. Defining the




This was a multi-institutional randomized open-label phase
IB trial conducted in 6 medical centers. Eligible patients
were randomly assigned to receive oral vinorelbine tartrate
(Navelbine® softgel capsules) at one of three predefined flat
dose levels (30 or 40 or 50 mg) taken orally 3 times a week
before lunch. Treatment continued until disease progres-
sion or occurrence of treatment related toxicity grade 3 orhigher or patient’s decision or maximum 24 months treat-
ment. The study was conducted in accordance with the
Declaration of Helsinki and Scientific Committees of in-
volved institutions approved the protocol.
Patients
Eligibility criteria were similar to those of the phase IA
part of the trial [22]. Eligible patients had to sign an in-
formed consent before participation. Eligibility criteria
were as follows: age 16–75 years; performance status 0
to 2 according to the WHO scale; minimum life expect-
ancy of 16 weeks; adequate bone marrow, hepatic and
renal functions; absence of brain metastasis; metastatic
and locally advanced hormonal refractory prostate, or
previously treated metastatic breast cancer or non-small
cell lung cancer previously treated with no more than
two chemotherapeutic regimens; no other concurrent
anticancer chemotherapy; serum creatinine within nor-
mal limits; hemoglobin of at least 10 g/L, white blood
cell counts ≥3.5x109/L; absolute neutrophil count (ANC)
≥1.5x109/L; platelets ≥150x109/L; total serum bilirubin
≤1.5× upper normal limit (UNL); transaminases ≤ 2.0 ×
upper normal limit (UNL) unless attributed to liver me-
tastases. Concurrent limited field radiation therapy (RT)
and any previous RT was allowed. Exclusion criteria were
the following: major active infection; more than two prior
chemotherapy regimens for metastatic disease; chemo-
therapy administered within 28 days prior to start of
metronomic vinorelbine; extensive liver metastases occu-
pying more than half the liver; ongoing anti-coagulation
therapy; pregnancy or breastfeeding and any of the follow-
ing if occurred within 12 months prior to randomization:
myocardial infarction, severe/unstable angina, coronary/
peripheral artery bypass graft, congestive heart failure,
cerebrovascular accident or transient ischemic attack, pul-
monary embolism, cardiac dysrhythmias of grade >/= 2,
atrial fibrillation of any grade or heart rate corrected QT
interval (QTc) > 450 msec for males or > 470 msec for
females, uncontrolled hypertension (> 150/100 mmHg
despite optimal medical therapy). Patients with severe
acute or chronic medical or psychiatric condition that
in the judgment of the investigator would make the
patient inappropriate for entry into the trial would also
be excluded. Drop-off reasons included serious adverse
events possibly related to the study drug, conditions
requiring therapeutic intervention not permitted by the
protocol and patients personal preference. The consort
diagram of the study is shown in Figure 1.
Follow up and sampling
Patients attended outpatient clinics every two weeks
during he first two months on treatment and monthly
thereafter for clinical assessment and blood sampling.
For pharmacokinetic analysis, 5 ml whole blood samples
Figure 1 Consort diagram describing the main characteristics of the present clinical study.
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fore treatment initiation and at follow-up visits before
taking oral vinorelbine. Samples were stored at −20°C
until analysis. Additional blood plasma and blood RNA
were obtained prior to treatment, 4 weeks later and on a
monthly schedule in consented patients in order to study
circulating angiogenesis biomarkers. Both plasma and
PAXgene RNA™ tubes (Qiagen, Thessaloniki, Greece)
were stored at −80°C until analysis.
Study endpoints
The primary clinical endpoint was time to treatment
failure (TTF). TTF rates per treatment arm would be
compared at 4 and 6 months. Secondary endpoints
were progression-free survival (PFS), time-to-progression,
toxicity, correlation of baseline blood concentrations of
angiogenesis-associated surrogate markers with treatment
efficacy measures, and pharmacokinetics.
Toxicity was evaluated according to the National Cancer
Institute Common Toxicity Criteria V3. Acute toxicity
was considered any adverse event that occurred duringthe first 8 weeks of treatment, while chronic toxicity
was characterized any side effect that was recorded four
months after the initiation of treatment. Toxicity that
occurred between 8 weeks to 4 months of treatment
was characterized sub-acute.
Treatment response was evaluated in patients that had
completed at least 6 weeks of treatment and had at least
one follow-up tumor assessment. Baseline tumor assess-
ment was performed within 4 weeks prior to treatment
initiation and thereafter every 2 months until documenta-
tion of response. Documented response should be con-
firmed after 4 weeks and should be regularly assessed every
4 months thereafter. Chest X-rays, computerized tomo-
graphic (CT) scans, ultrasound imaging studies and clinical
measurements were used as appropriate. Response was
documented using the RECIST response criteria for solid
tumors [27] and Bubley Criteria for prostate cancer [28].
Circulating biomarkers
Plasma concentrations of basic fibroblast growth factor
(FGF2), vascular endothelial growth factor-A (VEGFA),
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determined by using commercially available quantitative
sandwich enzyme immunoassays. In particular, Quantikine
kits (R&D Systems, Inc., Minneapolis, USA) were used for
FGF2, VEGF, VEGFR2 and IL8, and the ChemiKine Human
TSP1 EIA Kit for TSP1 (Chemicon International, Inc.,
Temecula, CA, USA). Protocols, procedures, and equip-
ment were used according to the manufacturer’s instruc-
tions. The lower detection limits for FGF2, VEGF, VEGFR2,
IL8 and TSP1 were respectively 10, 31.2, 78.1, 31.2 and
9.8 pg/mL and the means for intra- and inter-assay coef-
ficients of variation were 3.6 to 7.8 and 6.5 to 10.0,
respectively. Optical densities were determined using a
microfilter plate reader (DAS-A3, Roma, Italy) with
filters for 450 nm (IL8, VEGF, VEGFR-2) and 490 nm
(FGF2, TSP1). All analyses were carried out in dupli-
cate. Samples available for each biomarker are shown
in the REMARK diagram of Figure 2 [29].
RNA extraction, reverse transcription and real time
PCR arrays
Peripheral blood was drawn in PAXgene tubes and kept
frozen at −80°C. Total RNA was extracted with the
PAXgene blood RNA kit, according to the manufacturer’s
instructions (PreAnalytiX/Qiagen), within 6 months from
collection. The additive contained in the PAXgene tubes
reduces in vitro RNA degradation and minimizes in vitro
gene induction [30]. RNA was extracted from 4 patients
who either had an objective response (three patients) or
TTF >6 months (1 patient) and 4 patients who relapsed
early (within 2 months of the initiation of treatment). The
analysis was done in mirrored samples: before treatment
initiation and 4 weeks after treatment initiation. RNAMetronomic Ora
treated pat
eligible, N
12 out of 73 (5 progressin















Figure 2 REMARK diagram for biomarker studies.integrity was checked by both conventional RNA electro-
phoresis and Agilent bioanalizer 2100. High quality RNA
was reverse transcribed and analyzed on a PCR array plat-
form (PAHS-024 F, SABiosciences) and the expression
levels of 84 genes involved in angiogenesis were deter-
mined by using real time PCR.
Only RNAs with RNA integrity number (RIN) >7 were
used for reverse transcription and further processing.
For reverse transcription the SABiosciences RT2 First
Strand kit was used. In all cases RNA of 0.5 μg was
reversed transcribed. Simultaneous quantification of 84
key genes involved in angiogenesis was done by using
the angiogenesis RT2 profiler PCR Array (PAHS-024 F,
SABiosciences). Relative expression was determined
with the Light Cycler 480 instrument (Roche) and the
ΔΔCt method [31].
Pharmacokinetics
Whole blood samples were shipped on dry ice to the
Institute de Recherché Pierre Fabre, Castres, France, for
analysis. Concentrations of vinorelbine (VRL) and its
main metabolite, 4-O-deacetylvinorelbine (DVRL) were
quantified using a sensitive LC/MS/MS method previ-
ously reported [32].
Statistical analysis
Analysis was performed on an intent-to-treat basis. Re-
garding the definition of endpoints reported, time to
treatment failure (TTF) was calculated as the time from
random assignment to disease progression or death from
any cause or early treatment discontinuation. Time to
progression (TTP) was calculated as the time from ran-
dom assignment to disease progression. Progression-freel Vinorelbine 
ients,
 = 73
g and 7 with disease 















Table 1 Patients’ characteristics
Oral vinorelbine dose arms
30 mg 40 mg 50 mg
Patients N 27 24 22
Age median 67 66 67
range 43-74 48-75 44-75
Gender Male 18 (66.6%) 17 (70.8%) 15 (68.2%)
Female 9 (33.4%) 7 (29.2%) 7 (31.8)
Cancer type Breast 7 (26.0%) 6 (25.0%) 7 (31.8%)
Prostate 8 (29.6%) 7 (29.2%) 7 (31.8%)
NSCLC 12 (44.4%) 11 (45.8%) 8 (36.4%)
PS 0 8 (29.6%) 10 (41.6%) 8 (36.4%)
1 15 (55.6%) 11 (45.8%) 12 (54.6%)
2 4 (14.8%) 3 (12.6%) 2 (9.0%)
Prior chemotherapy 0 5 (18.6%) 4 (16.6%) 5 (22.8%)
1 13 (48.2%) 12 (50.0%) 11 (50.0%)
2 9 (33.4%) 8 (33.4%) 6 (27.2%)
Prior radiotherapy 14 (51.8%) 8 (33.4%) 11 (50.0%)
Prior hormonotherapy 12 (44.4%) 11 (44.8%) 13 (59.0%)
Organs with metastases lung 15 (55.6%) 14 (58.4%) 10 (45.4%)
liver 8 (29.6%) 4 (16.6%) 3 (13.6%)
bone 18 (66.6%) 15 (62.6%) 9 (41%)
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assignment to disease progression or death from any
cause. Survival was calculated as the time from random
assignment to death from any cause. Event-free patients
at last contact were censored. Time-to-event distribu-
tions were estimated using Kaplan-Meier curves while
the log-rank test was used for comparisons.
The Fisher’s exact test and the Jonckheere-Terpstra
exact test were used to examine differences in toxicity
rates between treatment groups. Association between
biomarkers at baseline and response/activity (patients
without objective response and/or progressing within
4 months vs those with objective response or PFS >
4 months vs healthy controls) was assessed with the
Kruskall-Wallis test. Correlations among biomarkers were
calculated using the Pearson’s correlation test. Significance
was determined at the level of 5% (two-sided).
The sample size for this 3-arm randomized study was
estimated under the assumption that the expected 4 and
6 month TTF rate for the 30 mg, 40 mg and 50 mg
groups would be 10%, 30% and 50% and 5%, 20% and
40% respectively. Using a global chi-square test at the
2.5% level of significance (Bonferroni adjusted) the study
had 80% power to reject the null hypothesis that all the
arms had the same TTF rate [33].
Results
Between January 2006 and January 2007, 73 eligible pa-
tients were recruited into the trial. The median age of the
patients was 67 years for the 30 and 50 mg dose levels and
66 years for the 40 mg dose level arm. The majority of pa-
tients (68.5%) were male, they had a PS 1–2 (64.4%) and
the most common cancer was NSCLC (42.5%), while
80.8% had received prior chemotherapy and the most
common metastatic site were bones (57.5%). Baseline pa-
tients’ characteristics are shown in Table 1.
Clinical outcomes
Antitumor efficacy was seen at all dose arms. Confirmed
partial remissions were documented in four cases of pa-
tients. Those were two NSCLC patients who received
30 mg (response duration 4 weeks) and 50 mg (response
duration 100 weeks) one breast cancer patient treated at
40 mg (response duration 18 weeks) and one prostate can-
cer patient treated at 50 mg (response duration 30 weeks)
(Figure 3). Eleven patients achieved a TTF longer than
6 months. No arm was found superior at the primary end-
point (Table 2, Figure 4). The median time to treatment
failure was eight weeks in all three arms, while the
4 month TTF rate point estimates and 95% Confidence
Intervals (CIs) for the 30 mg, 40 mg and 50 mg vinorelbine
groups were 25.9% (11.1%-46.2%), 33.3% (15.6%-55.3%)
and 18.2% (5.2%-40.3%) respectively. The p-value of the
Fisher’s exact test for equality of the rates is 0.56. Similarly,the 6 month TTF rate point estimates and 95% CIs were
respectively 22.2% (8.6%-57.7%), 8.3% (1.0%-27.0%) and
13.6% (2.91%-34.9%) for the 30 mg, 40 mg and 50 mg
groups respectively. The p-value of the Fisher’s exact test
is 0.39. In both cases the TTF rate did not vary statistically
significant among the treatment arms. No differences were
noticed among the three arms with regard to PFS and
overall survival.
The side effects observed were generally mild and negli-
gible. No differences in grade 3 and 4 acute toxicities were
seen among the three dose levels. The only statistically
significant difference observed was lymphopenia (worse in
lower dose levels) and gastrointestinal (worse at dose level
40) (Table 3). Chronic toxicities did not occur.Pharmacokinetics
Trough levels of vinorelbine were measured in 237 blood
samples drawn from 44 consented patients (61% of treated
patients) over a time that spanned duration of therapy
from 2 to 36 weeks. Steady state concentrations were
similar to those recorded in the phase IA trial with no
evidence of accumulation over time (Figure 5). Mean
values and standard deviation (SD) for the 30 mg dose
was 1.8 ng/ml (SD 1.10), 2.2 ng/ml (SD 1.87) for the
40 mg dose and 2.6 ng/ml (SD 0.69) for the 50 mg dose.
A dose proportional increase of steady state concentrations
Figure 3 Objective tumor responses. Objective responses documented in a prostate cancer patient treated at 50 mg dose and a breast cancer
patient treated at 40 mg dose.
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(ANOVA p value = 0.5).
Circulating angiogenesis modulating proteins and
gene transcripts
Of the investigated angiogenesis modulating proteins,
baseline pre-treatment levels of FGF2 and IL8 were found
to have a power to predict favorable response to metro-
nomic vinorelbine (p value = 0.02 and 0.006 respectively).
In particular, patients with baseline levels approximatingTable 2 TTF rate point estimates and 95% confidence interva
(TTF refers to time from treatment initiation to discontinuatio
Patients (%) on treatment
Vinorelbine dose arm (mg) At 4 months
30 25.9% (11.1-46.2%)
40 33.3% (15.6-55.6%)
50 18.2% (5.2-20.3%)those of healthy individuals had a chance to have a favor-
able outcome to therapy. VEGF and VEGFR2 baseline
levels did not differ between patients with favorable versus
non-favorable therapy outcome and TSP-1 data were in-
conclusive at a marginal p-value (Table 4).
Data analysis of circulating gene transcripts by using
the ΔΔCt method revealed that TEK gene transcript
was significantly up-regulated before treatment in non
responders, while gene transcripts of SPHK1, CCL2, KDR,
CCL1, FGF1, FGFR3, FIGF, HAND2, IFNA1, IGF1, MDK,ls for the 30 mg, 40 mg and 50 mg vinorelbine groups
n for any reason)
At 6 months





Figure 4 Time to treatment failure probability curve.
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the CXCL9 gene was down-regulated 2.92 fold. FGF2
transcript post treatment initiation was found to be
up-regulated in non responders and IL8, PGF, FIGF,
IGF1 gene transcripts were down-regulated more than
2 folds (Figure 6).Table 3 Worse toxicity events by grade and treatment dose g
Label of variable
Treatment dose group
Vinorelbine 30mg Vinorelbine 4
Grade Grade
1 2 3 4 1 2
Hemoglobin 17 2 1 . 16 3
Leukocytes 5 . 1 2 2 3
Neutrophils 1 1 2 1 5 1
Platelets 4 . . . 1 .
Neuropathy Sensor 1 1 . . 2 .
Diarrhea 2 . . . 1 .
Constipation 2 . . . 2 .
Fatigue 7 . . . 5 .
Metabolic/Laboratory 6 1 1 . 3 2
Pain 1 2 2 . 6 .
Hemoptysis . 1 . . 1 .
Edema: limb . . . . 1 .
Upper Respiratory 3 . 2 . 3 .
Febrile Neutropenia . . . . . .
Gastrointestinal 1 . . . 6 2
Weight (Gain- Loss) . 2 1 . 1 .
Fever . 1 . . 1 .
Lymphopenia . 3 . . 2 1Discussion
This was a dose selection study of metronomic oral
vinorelbine for the treatment of metastatic NSCLC,
breast and prostate cancer patients that had relapsed
from a previous therapy. The primary clinical endpoint
of this trial was set to be time to treatment failureroup- N of patients
FISH test p value
0mg Vinorelbine 50mg
Grade
3 4 1 2 3 4
1 . 14 2 . . ND
1 2 3 3 2 1 ND
1 2 3 1 2 2 ND
. . 1 . . . ND
. . 3 . . . ND
1 . . . . . ND
. . 1 . 1 . ND
1 . 4 . . 1 ND
1 . 5 1 . . ND
. . 2 1 . . ND
. . . . . . ND
1 . 1 . 1 . ND
. . . . . . ND
1 . . . . . ND
. . 1 . . 0,035
. . . . . . ND
. . 1 1 . . ND
1 . . . . . 0,032
Figure 5 Trough blood concentrations of vinorelbine over time. Scatter plots of serial trough concentrations of VLR and its active metabolite
DVLR over time in a patient prostate cancer patient treated at 50 mg dose arm (A) and a breast cancer patient treated at 40 mg (B) and median
(plus SEM) values of steady state levels of all patients treated at the three dose arms (C).
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is a composite measure that co-estimates time from
randomization to discontinuation of treatment for any
reason, including disease progression, treatment tox-
icity, and death. It trade-offs efficacy and toxicity, whichis of major importance for metronomic therapy, espe-
cially when tested in patients with diverse tumor types
[34]. This trial failed to demonstrate superiority in any
of the three doses investigated at the primary endpoint,
since median TTF was six weeks for all three arms and
Table 4 Assessment of circulating angiogenesis modulating proteins as therapy activity predictors
Treatment failure Objective response or TTF > 4monts Healthy controls
FGF2 (pg/ml) N 5 7 8
median 3.4 1.8 0.8
range (1.9-23.7) (0.4-14.8) (0.2-2.3)
p-value 0.02*
IL8 (pg/ml) N 5 7 8
median 27.2 5.8 5.8
range (12.2-61.9) (2.8-18.9) (1.1-7.5)
p-value 0.006**
TSP-1 (ng/ml) N 5 7 8
median 125.1 69.6 67.3
range (85.1-328.4) (24-452) (9-710.1)
p-value 0.047
VEGF (pg/ml) N 5 7 10
median 1552 428,6 2094
range (804.3-2785) (252.4-3116) (1122-2387)
p-value 0.074
VEGFR-2 (pg/ml) N 5 7 8
median 13680 13275 12328
range (8945-16465) (7455-18065) (8235-17615)
p-value 0.657
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the three arms either. Considering the objective tumor
responses, partial remission was confirmed in four cases
and lasted up to 49 weeks. Two of the objective re-
sponses occurred in patients treated at the upper dose
arm and lasted longer compared to objective responses
that were achieved with the lower doses. Major finding
of this trial, as in the previous one, was that activity
came at no cost of clinically significant toxicity, which is
a hallmark of metronomic chemotherapy [19]. In addition,
toxicities that are known to occur with drugs that inhibit
the VEGF – VEGFR-2 pathway were not seen with metro-
nomic vinorelbine, which supports that a combination
of these two antiangiogenic therapies would be probably
feasible [35,36].
Antiangiogenic therapy is known to work optimally if
endothelial cells are exposed to steady levels of inhibi-
tors [11,37]. Both vinorelbine and its active metabolite
achieved steady state concentrations at the low nanomolar
range, which was found in vitro to optimally inhibit pro-
liferation of endothelial cell and induce expression of
endogenous anti-angiogenic molecules [38].
Similarly to the phase IA study, we found that low
baseline levels of circulating endogenous promoters of
angiogenesis and in particular IL8 and FGF2 could pre-
dict clinical benefit from treatment with metronomic
vinorelbine [22]. In addition, we investigated circulatingtranscripts of a panel of 84 key genes involved in modu-
lating the biological processes of angiogenesis. Among
them, high baseline levels of TEK transcripts were asso-
ciated with resistance to therapy. TEK, a biomareker of
hemangioblasts, appears to be a potential predictor of
refractoriness to antiangiogenic therapy [39,40]. This is
possibly related to its function as an endothelial cell sur-
face receptor for angiopoietins ANGPT1, ANGPT2 and
ANGPT4, that are regulators of survival and adhesion of
endothelial cells and promoters of vascular stability and
quiescence [41].
Overall, this study failed to specify the optimal metro-
nomic dosage of oral vinorelbine by the primary end-
point. However it boosts the findings of the phase IA
dose-ranging study by confirming that metronomic oral
vinorelbine can safely be administered at doses up to
50 mg three time a week and that it can yield long lasting
antitumor activity at the this dose without overt toxicity.
In addition the steady-state nanomolar concentrations and
the association of angiogenesis modulating factors with its
activity denotes that the mechanism of antitumor activity
of metronomic therapy is most likely antiangiogenic, as
suggested by other investigators too [26,42].
Conclusion
In conclusion, by taking into consideration the antitumor
activity and response duration, negligible toxicity of the
Figure 6 Transcript levels of 84 angiogenesis-related genes graphed against treatment outcome Scatter plots comparing circulating
pretreatment gene transcript levels of responders versus non-responders. The graphs plot the log10 of normalized gene expression levels
between the two conditions, responders (x-axis) and non-responders (y-axis). Dots outside the area between the two lines indicate fold
differences larger than a threshold of 2. The red dots in the upper left corner readily identify up-regulated genes, and the green dots in the lower
right corner readily identify down regulated genes.
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time, we suggest that metronomic oral vinorelbine war-
rants further investigation in combination with conven-
tional chemotherapy regimens or targeted angiogenic
therapies at the dose of 50 mg given every other day,
three times a week. Finally these data add support to
the concept that metronomic scheduling provides a
new future for using cytotoxic chemotherapy, especially
in cases of incurable metastatic cancers [43].
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